MX2021010759A - Regimen de dosificacion para un agonista de los receptores de s1p. - Google Patents

Regimen de dosificacion para un agonista de los receptores de s1p.

Info

Publication number
MX2021010759A
MX2021010759A MX2021010759A MX2021010759A MX2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A MX 2021010759 A MX2021010759 A MX 2021010759A
Authority
MX
Mexico
Prior art keywords
dosage regimen
receptor agonist
dosage
daily dosage
regimen
Prior art date
Application number
MX2021010759A
Other languages
English (en)
Inventor
Robert Schmouder
Thomas Dumortier
Michael Looby
David Olivier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021010759(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021010759A publication Critical patent/MX2021010759A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los moduladores o agonistas de los receptores de S1P se administran siguiendo un régimen de dosificación en donde, durante los días iniciales del tratamiento, la dosificación diaria es más baja que la dosificación diaria convencional.
MX2021010759A 2008-12-22 2011-06-17 Regimen de dosificacion para un agonista de los receptores de s1p. MX2021010759A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967208P 2008-12-22 2008-12-22
US21853009P 2009-06-19 2009-06-19
US24671509P 2009-09-29 2009-09-29

Publications (1)

Publication Number Publication Date
MX2021010759A true MX2021010759A (es) 2022-07-19

Family

ID=41667217

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011006623A MX2011006623A (es) 2008-12-22 2009-12-21 Regimen de dosificacion para un agonista de los receptores de s1p.
MX2021010759A MX2021010759A (es) 2008-12-22 2011-06-17 Regimen de dosificacion para un agonista de los receptores de s1p.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011006623A MX2011006623A (es) 2008-12-22 2009-12-21 Regimen de dosificacion para un agonista de los receptores de s1p.

Country Status (41)

Country Link
US (11) US20110257133A1 (es)
EP (7) EP3409274B1 (es)
JP (6) JP2012513401A (es)
KR (1) KR101347919B1 (es)
CN (1) CN102264359A (es)
AR (1) AR074826A1 (es)
AU (1) AU2009330176C9 (es)
BR (1) BRPI0923500A2 (es)
CA (1) CA2747802C (es)
CL (2) CL2011001529A1 (es)
CO (1) CO6390117A2 (es)
CR (1) CR20110274A (es)
CU (1) CU20110136A7 (es)
CY (4) CY1116990T1 (es)
DK (3) DK2379067T3 (es)
EA (1) EA201100978A1 (es)
EC (1) ECSP11011222A (es)
ES (3) ES2760607T3 (es)
FR (1) FR20C1060I1 (es)
HN (1) HN2011001759A (es)
HR (3) HRP20151190T1 (es)
HU (4) HUE048717T4 (es)
IL (3) IL213170A0 (es)
LT (3) LT3453387T (es)
LU (1) LUC00183I2 (es)
MA (1) MA32981B1 (es)
ME (2) ME03802B (es)
MX (2) MX2011006623A (es)
NO (1) NO2020038I1 (es)
NZ (1) NZ593065A (es)
PE (1) PE20120337A1 (es)
PL (3) PL2379067T3 (es)
PT (3) PT3453387T (es)
RS (2) RS60666B1 (es)
SG (1) SG171404A1 (es)
SI (3) SI3453387T1 (es)
TN (1) TN2011000272A1 (es)
TW (1) TW201028143A (es)
UY (1) UY32352A (es)
WO (1) WO2010075239A1 (es)
ZA (2) ZA201103863B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800208A (zh) 2008-03-17 2015-07-29 埃科特莱茵药品有限公司 选择性s1p1受体激动剂的给药方案
EP3409274B1 (en) 2008-12-22 2019-11-20 Novartis AG Dosage regimen for a s1p receptor agonist
CA3129729A1 (en) 2009-09-29 2011-04-07 Novartis Ag Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
EA201201515A1 (ru) * 2010-05-06 2013-08-30 Новартис Аг Схема приема производных диарилсульфидов
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
DK2675893T3 (en) 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
CN104540800B (zh) 2012-08-17 2017-05-10 埃科特莱茵药品有限公司 制备(2z,5z)‑5‑(3‑氯‑4‑((r)‑2,3‑二羟基丙氧基)苯亚甲基)‑2‑(丙亚氨基)‑3‑(邻甲苯基)噻唑烷‑4‑酮的方法及在该方法中所用的中间产物
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
IL305337A (en) * 2014-04-10 2023-10-01 Novartis Ag A therapeutic regimen containing an immediate release dose of an S1P modulator
KR20230147768A (ko) 2014-12-11 2023-10-23 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
CA3002540C (en) * 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
AU2016284162A1 (en) 2015-06-22 2018-02-01 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
JP2020507610A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
CN113332435B (zh) * 2021-06-18 2022-10-18 广州中医药大学(广州中医药研究院) 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
JP2004507552A (ja) 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体
BR0311173A (pt) 2002-05-16 2005-03-15 Novartis Ag Uso de agentes de ligação do receptor de edg em câncer
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
NZ554720A (en) * 2004-11-29 2011-04-29 Novartis Ag Compositions and uses of fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol)
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
WO2006085316A2 (en) * 2005-02-10 2006-08-17 G.I. View Ltd. Advancement techniques for gastrointestinal tool with guiding element
SG187458A1 (en) * 2007-10-12 2013-02-28 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
CN104800208A (zh) 2008-03-17 2015-07-29 埃科特莱茵药品有限公司 选择性s1p1受体激动剂的给药方案
EP2303250A1 (en) 2008-06-20 2011-04-06 Novartis AG Paediatric compositions for treating1 multiple sclerosis
JO3044B1 (ar) 2008-12-22 2016-09-05 Novartis Ag نظام تناول جرعة لمنبه مستقبل s1p
EP3409274B1 (en) 2008-12-22 2019-11-20 Novartis AG Dosage regimen for a s1p receptor agonist

Also Published As

Publication number Publication date
DK3409274T3 (da) 2019-12-16
HUE048717T4 (hu) 2022-02-28
HUS2000046I1 (hu) 2020-12-28
PT2379067E (pt) 2015-12-23
HUE048717T2 (hu) 2020-08-28
EP3677260A1 (en) 2020-07-08
SG171404A1 (en) 2011-07-28
SI3453387T1 (sl) 2020-10-30
JP2016135752A (ja) 2016-07-28
MX2011006623A (es) 2011-07-12
PL2379067T3 (pl) 2016-02-29
CA2747802A1 (en) 2010-07-01
NZ593065A (en) 2012-11-30
SI3409274T1 (sl) 2020-03-31
RS60666B1 (sr) 2020-09-30
EP2379067B1 (en) 2015-09-02
FR20C1060I1 (fr) 2020-12-25
CU20110136A7 (es) 2012-01-31
LUC00183I2 (es) 2024-07-01
HRP20201167T1 (hr) 2020-12-11
BRPI0923500A2 (pt) 2018-05-29
IL278914A (en) 2021-01-31
AU2009330176A1 (en) 2011-07-07
HRP20192175T1 (hr) 2020-03-20
PT3409274T (pt) 2019-12-17
CL2013001558A1 (es) 2013-10-25
SI2379067T1 (sl) 2016-01-29
US20200330407A1 (en) 2020-10-22
CY1123255T1 (el) 2021-10-29
AR074826A1 (es) 2011-02-16
JP2012513401A (ja) 2012-06-14
ME03594B (me) 2020-07-20
LT3453387T (lt) 2020-08-25
JP2022103194A (ja) 2022-07-07
JP2019167360A (ja) 2019-10-03
TN2011000272A1 (en) 2012-12-17
CO6390117A2 (es) 2012-02-29
PL3453387T3 (pl) 2020-11-02
LTPA2020005I1 (lt) 2020-12-10
HN2011001759A (es) 2013-11-26
EP2379067A1 (en) 2011-10-26
CA2747802C (en) 2021-02-09
JP7329965B2 (ja) 2023-08-21
PL3409274T3 (pl) 2020-06-01
ECSP11011222A (es) 2011-08-31
JP2017141238A (ja) 2017-08-17
ES2760607T3 (es) 2020-05-14
LT3409274T (lt) 2020-02-10
US20220142949A1 (en) 2022-05-12
AU2009330176C1 (en) 2016-12-08
US20190091180A1 (en) 2019-03-28
PT3453387T (pt) 2020-08-11
AU2009330176C9 (en) 2017-01-05
NO2020038I1 (no) 2020-11-18
CY1116990T1 (el) 2017-04-05
RS59857B1 (sr) 2020-02-28
HUE052048T2 (hu) 2021-04-28
CY2020036I2 (el) 2021-06-25
US20100160259A1 (en) 2010-06-24
EP3409274A1 (en) 2018-12-05
DK3453387T3 (da) 2020-08-10
KR20110096175A (ko) 2011-08-29
HUE026869T2 (en) 2016-08-29
TW201028143A (en) 2010-08-01
EP3409274B1 (en) 2019-11-20
KR101347919B1 (ko) 2014-01-07
EP2907511A1 (en) 2015-08-19
US20110257133A1 (en) 2011-10-20
DK2379067T3 (en) 2015-12-07
EP3120844A1 (en) 2017-01-25
US20140066657A1 (en) 2014-03-06
CL2011001529A1 (es) 2012-02-24
US20160263061A1 (en) 2016-09-15
US20170189353A1 (en) 2017-07-06
ES2552823T3 (es) 2015-12-02
US20180289638A1 (en) 2018-10-11
CY1122812T1 (el) 2021-05-05
CY2020036I1 (el) 2021-03-12
IL274756A (en) 2020-07-30
EA201100978A1 (ru) 2012-01-30
WO2010075239A1 (en) 2010-07-01
EP4098256A1 (en) 2022-12-07
JP2014144970A (ja) 2014-08-14
CR20110274A (es) 2011-07-19
US20160081949A1 (en) 2016-03-24
CN102264359A (zh) 2011-11-30
UY32352A (es) 2010-07-30
AU2009330176B2 (en) 2014-03-06
ME03802B (me) 2021-04-20
ZA201205942B (en) 2013-03-27
EP3453387B1 (en) 2020-06-03
IL213170A0 (en) 2011-07-31
MA32981B1 (fr) 2012-01-02
US20140148415A1 (en) 2014-05-29
HRP20151190T1 (hr) 2016-01-01
ES2810823T3 (es) 2021-03-09
PE20120337A1 (es) 2012-04-24
ZA201103863B (en) 2012-10-31
EP3453387A1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
MX2021010759A (es) Regimen de dosificacion para un agonista de los receptores de s1p.
MX2011006625A (es) Regimen de dosificacion de un agonista de los receptores de s1p.
PH12017501495A1 (en) Dosage regimen of an s1p receptor modulator
MX2009006304A (es) Nuevos compuestos de oxadiazol.
MX2012000704A (es) Agonistas de gpr119.
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
CL2008002129A1 (es) Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer.
MX341025B (es) Terapia de combinacion.
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
MX2011013437A (es) Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos.
GB0812642D0 (en) Compounds
MX2007010752A (es) Usos oftalmicos de moduladores de receptor s1p.
CL2009002017A1 (es) Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria.
JO2730B1 (en) Medications for the treatment of endometriosis
JO2979B1 (en) Cyclopropyl compounds
CU20130155A7 (es) Régimen de dosificación para un agonista de los receptores de s1p
UA106219C2 (ru) Модуляторы толл-подобных рецепторов
CL2010000497A1 (es) Uso de compuestos derivados de indol para el tratamiento del dolor visceral; compuestos específicos derivados de indol; procedimiento de preparación de un compuesto; composición farmacéutica y uso para el tratamiento de una condición causada por la acción de nos.
UA105483C2 (uk) Похідні ізохінолінону, композиція на їх основі та застосування як інгібіторів рі3k